Noxopharm Increases Existing Funding Agreement

  • Dec 03, 2019 AEDT
  • Team Kalkine

Noxopharm Ltd (ASX: NOX), a clinical-stage Australian drug development company, has secured an increase to its existing funding agreement with two New York institutional investors- Lind Global Macro Fund, LP and CST Investment Fund.

  • The agreement comprises of an increase of $2.4 million (face value) secured convertible security with a lock-up period until 30 March 2020;
  • This capital will be used to fund a small study in healthy volunteers required by the FDA.

At AEST 1:16PM, the stock was trading at $0.360 per share, down by 2.7%.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK